期刊文献+

变性高效液相色谱分析巯嘌呤甲基转移酶基因多态性位点 被引量:2

Analysis of Thiopurine Methyltransferase Gene Polymorphism by Denaturing HPLC
下载PDF
导出
摘要 目的 应用变性高效液相色谱技术(DHPLC)分析巯嘌呤甲基转移酶(TPMT)基因多态性位点.方法 用以PCR为基础的DHPLC,检测健康成人和脐血以及急性白血病病人,TPMT基因第5外显子G238C、第7外显子G460A和第10外显子A719G的3个多态性位点.结果 健康成人、脐血和急性白血病病人全部DNA样本,TPMT基因外显子区的3个位点的多态性频率为3.49%,远低于白种人和非洲人.变异的位点仅为第10外显子A719G,且均为杂合变异.TPMT第5外显子630例标本的色谱峰均为单峰.第7外显子有316例为单峰,214(34%)为杂合峰.将单峰标本进行1:1混合后重新进样也有杂合峰出现.经DNA测序分析,证实此区无序列变异;杂合峰标本在54和60℃为单峰,55~59℃均为杂合峰.而单峰标本峰形未随温度发生变化.说明DHPLC的检测误差并不是柱箱温度不合适引起的.第10外显子有608例为单峰,杂合峰为22例,其中10/22例标本进行DNA直接测序,证实为杂合变异.结论 DHPLC技术能快速筛选出TPMT第5和第10外显子区的多态性位点,但不能检测出第7外显子的多态性位点.因此,DHPLC不能作为单一方法进行TPMT基因多态性位点的检测. OBJECTIVE To develop a denaturing high perfomance liquid chromatographic(DHPLC) assay for high throughput genotyping of thiopurine methyltransferase( TPMT). METHODS The TPMT genotype was determined in an unrelated population of Chinese healthy blood donors, cords blood and patients with acute leukemia. The TPMT genotyping assay was based on polymrase chin reaction( PCR), DHPLC and direct DNA sequencing. The genotype pulymorphism focused on the TPMT exon5 G238C, TPMT exon7 Gd60A and TPMT exon10 A719G. RESULTS The frequency of TPMT gene pulymorphism in the Han nationality of Chinese population was low. The frequency of the polymorphism was 3.49%. The varied alleles were TPMT exon10 A719G. All of them were heterozygote. According to the results of DHPLC, the screening of SNPs in TPMT exon-5 and-10 were the same as direct DNA sequencing. The variation of the heterozygotes in exon-7 was high, which was different from the results of direct DNA sequencing. After changing the Tm of DNA step by step, all the samples showed single peak when the temperature was 54 and 60℃. But this result was unbelievable because No heterozygote was found in exon 7 in positive control. CONCLUSION It was necessary to test the sensitivity and accuracy of DHPLC, though DHPLC is used as an effective method of SNPs screening. DHPLC 'alone can not meet the need of clinics and research. The compensation of each other is very important.
出处 《中国药学杂志》 CAS CSCD 北大核心 2006年第18期1428-1430,共3页 Chinese Pharmaceutical Journal
关键词 变性高效液相色谱分析 巯嘌呤甲基转移酶基因 多态性 denaturing high perfomance liquid chromatographic thiopurine methytransferase gene polymorphism
  • 相关文献

参考文献6

  • 1COLLIE-DUGUID E S,PRITCHARD S C,POWRIE R H.The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations[J].Pharmacogenetics,1999,9:37-42.
  • 2COULTHARD S A,MATHESON E C,HALL A G.The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment[J].Nucleosides Nucleotides Nucleic Acids,2004,23:1385-1391.
  • 3HON Y Y,FESSING M Y,PUI C H.Polymorphism of the thiopurine S-methyltransferase gene in African-Americans[J].Hum Mol Genet,1999,8(2):371-376.
  • 4WUSK B,KULLAK-UBLICK G A,RAMMERT C.Thiopurine S-methyltransferase polymorphisms:efficient screening method for patients considering taking thiopurine drugs[J].Eur J Clin Pharmacol,2004,60(1):5-10.
  • 5KUBOTA T,CHIBA K.Frequencies of thiopurine S-methyltransferase mutant alleles(TPMT * 2,* 3A,* 3B and * 3C)in 151 healthy Japanese subjects and the inheritance of TPMT * 3C in the family of a propositus[J].Br J Clin Pharmacol,2001,51(5):475-477.
  • 6STANULLA M,SCHAEFFELER E,FLOHR T.Thiopurine methyltransferase(TPMT)genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia[J].JAMA,2005,293:1485-1489.

同被引文献17

  • 1顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 2Hagaman JT,Kinder BW,Eckman MH.Thiopurine S-methyltran-ferase testing in idiopathic pulmonary fibrosis:a pharmacogeneticcost-effectiveness analysis.Lung,2010;188(2):125-132.
  • 3Stocco G,Crews KR,Evans WE.Genetic polymorphism of inosinet-riphosphate-pyrophosphatase influences mercaptopurine metabolismand toxicity during treatment of acute lymphoblastic leukemia individ-ualized for thiopurine-S-methyl-transferase status.Expert Opin DrugSaf,2010;9(1):23-37.
  • 4National Cancer Institute. Cancer therapy evaluation program:common toxicity criteria,version 2.0,common toxicity criteria manua[Z].1999.
  • 5Pui CH,Evans WE. Treatment of acute lymphoblastic leukemia[J].New England Journal of Medicine,2006,(02):166-178.
  • 6Cheok MH,Pottier N,Kager L. Pharmacogenetics in acutelymphoblastic leukemia[J].Seminars in Hematology,2009,(01):39-51.doi:10.1053/j.seminhematol.2008.09.002.
  • 7Kishi S,Cheng C,French D. Ancestry and pharmacogenetics of antileukemic drug toxicity[J].Blood,2007,(10):4151-4157.
  • 8Jared T,Hagaman,Brent WH.Eckman. thiopurine S-Methyltranferase testing in idiopathic pulmonary fibrosis:a pharmacogenetic cost-effectiveness analysis[J].Lung,2010.125-132.
  • 9Relling MV,Gardner EE,Sandboru WJ. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing[J].Clinical Pharmacology and Therapeutics,2011,(03):387-391.
  • 10Marsh S,van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics[J].Clinical Pharmacology and Therapeutics,2009,(02):139-141.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部